---
title: Resuscitation and Capillary Reperfusion
nct_id: NCT04791995
overall_status: COMPLETED
sponsor: Medical University of Vienna
study_type: OBSERVATIONAL
primary_condition: Cardiac Arrest
countries: Austria
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04791995.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04791995"
ct_last_update_post_date: 2022-09-26
last_seen_at: "2026-05-12T07:13:14.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Resuscitation and Capillary Reperfusion

**Official Title:** REsuscitation and CAPillary rePerfusion - A Cohort Study With Prospective Inclusion

**NCT ID:** [NCT04791995](https://clinicaltrials.gov/study/NCT04791995)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Medical University of Vienna
- **Conditions:** Cardiac Arrest, Cardiac Arrest, Out-Of-Hospital, Cardiopulmonary Arrest, Cardiopulmonary Arrest With Successful Resuscitation
- **Start Date:** 2021-03-03
- **Completion Date:** 2022-05-01
- **CT.gov Last Update:** 2022-09-26

## Brief Summary

Persistent microperfusion alterations after return of spontaneous circulation (ROSC) are associated with poor survival. To our knowledge, no human studies evaluating microperfusion during cardiopulmonary resuscitation (CPR) with simple and pre-hospital available tests have been published. Capillary refill time (CRT) and skin-mottling-score (SMS) are parameters for microperfusion and evaluated in septic and cardiogenic shock. In animal studies, microperfusion was impaired during cardiac arrest, although not correlating with systemic blood pressure.

The aim of this study is to investigate the correlation between impaired microcirculation (as measured with CRT and SMS) during resuscitation and ROSC resp. neurological outcome. Our clinical impression in daily routine is, that the appearance of a patient undergoing CPR is often linked to the outcome. We hypothesize, that this is due to changes in microperfusion of the skin.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 95 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* All patients ≥18 years during cardiopulmonary resuscitation
* witnessed cardiac arrest

Exclusion Criteria:

* insufficient manpower (e.g. study team has to provide CPR)
* hypovolemia (exsanguination, anaphylaxis, sepsis as underlying cause)
* presumed or known COVID-19 disease
* hypo-/hyperthermia (\<36.0°, \>37.5°C)
* Raynaud's disease
* Peripheral arterial disease
```

## Primary Outcomes

- **Capillary refill time (CRT)** _(time frame: baseline (immediately after inclusion to the study))_ — Capillary refill time in seconds measured on one finger and one earlobe for ROSC vs. no ROSC

## Secondary Outcomes

- **Skin mottling score (SMS)** _(time frame: baseline (immediately after inclusion to the study = minute 0), minute 2, 4, 6, 8, (...) up to return of spontaneous circulation or death, whichever came first)_
- **Capillary blood lactate (Lac)** _(time frame: baseline (immediately after inclusion to the study, = minute 0), minute 4, 8, 12, 16, 20)_
- **Hospital mortality** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of CRT, SMS and Lac and 30 days good neurological outcome** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of CRT, SMS and Lac and hospital discharge good neurological outcome** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of CRT/SMS and lactate** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of SMS and CRT** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of time since cardiac arrest and CRT/SMS/lactate** _(time frame: baseline (immediately after inclusion to the study))_
- **Correlation of catecholamine demand during the first 48 hours after ROSC and CRT/SMS** _(time frame: from ROSC up to 48 hours after ROSC)_
- **Capillary refill time (CRT)** _(time frame: minute 2, 4, 6, 8, (...) up to return of spontaneous circulation or death, whichever came first)_

## Locations (1)

- Vienna Municipal Emergency Service, Vienna, Austria

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.vienna municipal emergency service|vienna||austria` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04791995.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04791995*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*